Dr Steven Wood

All publications

Journal articles

• Wood SL, Lopez-Guajardo A, Oliva M, Collins M, Clézardin P, Croset M & Brown JE (2024) #32. Identification of proteins regulating the metastatic spread of breast cancer to bone: Proteomic analysis of the role of the pro-metastatic transcription factor TWIST1 and the gene target micro-RNA (miR-10b). Journal of Bone Oncology, 45, 100570-100570.
• Wood SL, Lopez-Guajardo A, Oliva MR, Collins M, Pham K, Dunning M, Chambers EV & Brown JE (2024) #28. Identification of key proteins within prostate cancer derived exosomes and their role in priming the pre-metastatic niche. Journal of Bone Oncology, 45, 100566-100566.
• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen-positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15(8). View this article in WRRO
• Wood S, Lopez-Guajardo A, Oliva M & Brown J (2022) Identification of proteins which regulate the metastatic spread of breast cancer downstream of TWIST1. Bone Reports, 16, 101362-101362.
• Lovero D, D’Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R & Silvestris F (2022) Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 126(3), 419-429.
• Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI , Juarez P et al (2021) Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. Journal of Bone Oncology, 29, 100375-100375.
• D'oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C & Silvestris F (2021) Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases. Bone Reports, 14, 100840-100840.
• D’Oronzo- S, Wood- S & Brown- JE (2021) “The use of bisphosphonates to treat skeletal complications in solid tumours”. Bone, 115907-115907.
• Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. View this article in WRRO
• D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci MG, Stucci LS, Coleman RE & Silvestris F (2020) 30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients. Annals of Oncology, 31, S26-S26.
• Atala A (2019) Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis. Journal of Urology, 202(6), 1101-1101.
• Brown JE, Westbrook JA & Wood SL (2019) Dedicator of cytokinesis 4 : a potential prognostic and predictive biomarker within the metastatic spread of breast cancer to bone. Cancer Informatics, 18, 1-3. View this article in WRRO
• Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247(3), 381-391. View this article in WRRO
• Brown JE & Wood SL (2018) Novel mediators of breast cancer bone metastasis—insights from studies of gene-regulation and the global proteome. Annals of Translational Medicine, 6(S1), S71-S71.
• Probert C, Dottorini T, Speakman A, Hunt S, Nafee T, Fazeli A, Wood S, Brown JE & James V (2018) Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene, 38, 1751-1763. View this article in WRRO
• Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
• Hepburn S, Cairns DA, Jackson D, Craven RA, Riley B, Hutchinson M, Wood S, Smith MW, Thompson D & Banks RE (2015) An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis. PROTEOMICS - Clinical Applications, 9(5-6), 507-521.
• Wood SL, Pernemalm M, Crosbie PA & Whetton AD (2015) Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews, 41(4), 361-375.
• Brown JE & Wood SL (2014) Assessment of the Impact of Targeted Therapy on Metastatic Bone Disease in Renal Cancer. European Urology, 66(3), 510-511.
• Wood SL, Pernemalm M, Crosbie PA & Whetton AD (2014) The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treatment Reviews, 40(4), 558-566.
• Wood SL, Westbrook JA & Brown JE (2014) Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment. Cancer Treatment Reviews, 40(1), 139-152.
• Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ , Lewington AJP et al (2013) Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney International, 84(6), 1214-1225.
• Wood SL, Knowles MA, Thompson D, Selby PJ & Banks RE (2013) Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nature Reviews Urology, 10(4), 206-218.
• Wood SL & Brown JE (2012) Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treatment Reviews, 38(4), 284-291.
• Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ & Banks RE (2010) Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. British Journal of Cancer, 103(1), 101-111.
• Dent P, Wang Y, Gu Y-Z, Wood SL, Reardon DB, Mangues R, Pellicer A, Schonbrunn A & Sturgill TW (1997) S49 Cells Endogenously Express Subtype 2 Somatostatin Receptors Which Couple to Increase Protein Tyrosine Phosphatase Activity in Membranes and Down-regulate Raf-1 Activity In Situ. Cellular Signalling, 9(7), 539-549.
• Reardon DB (1997) Activation In Vitro of Somatostatin Receptor Subtypes 2, 3, or 4 Stimulates Protein Tyrosine Phosphatase Activity in Membranes from Transfected Ras-Transformed NIH 3T3 Cells: Coexpression with Catalytically Inactive SHP-2 Blocks Responsiveness. Molecular Endocrinology, 11(8), 1062-1069.
• REARDON DB, WOOD SL, BRAUTIGAN DL, BELL GI, DENT P & STURGILL TW (1996) Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochemical Journal, 314(2), 401-404.
• Dent P, Reardon DB, Wood SL, Lindorfer MA, Graber SG, Garrison JC, Brautigan DL & Sturgill TW (1996) Inactivation of Raf-1 by a Protein-tyrosine Phosphatase Stimulated by GTP and Reconstituted by Gαi/o Subunits. Journal of Biological Chemistry, 271(6), 3119-3123.
• Smith GM, Rothwell K, Wood SL, Yeaman SJ & Bownes M (1994) Specificity and localization of lipolytic activity in adult Drosophila melanogaster. Biochemical Journal, 304(3), 775-779.
• Yeaman SJ, Smith GM, Jepson CA, Wood SL & Emmison N (1994) The multifunctional role of hormone-sensitive lipase in lipid metabolism. Advances in Enzyme Regulation, 34, 355-370.
• Wood SL, Emmison N, Borthwick AC & Yeaman SJ (1993) The protein phosphatases responsible for dephosphorylation of hormone-sensitive lipase in isolated rat adipocytes. Biochemical Journal, 295(2), 531-535.
• Wood SL & Brown JE () Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 12(8), 2109-2109.

Chapters

• Wyld L, Cutress R & Morgan J (2024) Adjuvant Zoledronic Acid in Patients with Early Breast Cancer: Final Efficacy Analysis of the AZURE (BIG 01/04) Randomised Open-Label Phase 3 Trial, 50 Landmark Papers every Breast Surgeon Should Know (pp. 237-242). CRC Press
• Wood SL, Lopez-Guajardo A & Brown JE (2022) Identification of new therapeutic targets of bone cancers by proteomic strategies, Bone Cancer (pp. 783-803). Elsevier
• Brown J, Wood S & Lopez A (2021) Identification of new therapeutic targets of bone cancers by proteomic strategies In Heymann D (Ed.), Bone Cancer Bone Sarcomas and Bone Metastases - From Bench to Bedside (pp. 783-803). Elsevier
• Schoon JJ, Wood SL & Brown JE (2019) TKIs in Renal Cell Carcinoma, Oncogenomics (pp. 551-563). Elsevier
• Abdelhay E, Adiseshaiah PP, Aglietta M, Allègra M, Ascierto PA, Bastus NC, Basudan A, Berghuis AMS, Biasco G, Binato R , Borah A et al (2019) List of Contributors, Oncogenomics (pp. xv-xx). Elsevier
• Brown J, Wood S, Salawu A, Kroening H & D'Oronzo S (2019) Bone Metastases; Clinical Aspects In Martini L & Huhtaniemi I (Ed.), Encyclopedia of Endocrine Diseases (pp. 310-319). Oxford: Elsevier. View this article in WRRO
• Wood S, Salawu A, Kroening H, D’Oronzo S & Brown J (2019) Bone Metastases; Clinical Aspects, Encyclopedia of Endocrine Diseases (pp. 310-319). Elsevier
• Schoon JJ, Wood SL & Brown JE (2018) TKIs in renal cell carcinoma: What can we expect in the future?, Oncogenomics: From Basic Research to Precision Medicine (pp. 551-563). View this article in WRRO
• Wood SL & Brown JE (2014) The Application of ‘Omics’ Techniques for Cancers That Metastasise to Bone: From Biological Mechanism to Biomarkers In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases (pp. 125-153). Springer Netherlands

Conference proceedings papers

• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
• Wood* SL, Westbrook JA, Peng J, Selby PJ & Brown JE (2011) Development of a targeted strategy for enrichment and detection of calcium-binding proteins as potential biomarkers for bone metastases in breast cancer. Bone, Vol. 48(1) (pp S50-S51)